Amelioration of Severe TNBS Induced Colitis by Novel AP-1 and NF-κB Inhibitors in Rats
AP-1 and NF-κB inhibitors, namely, DTCM-G and DHMEQ, were investigated in male Wistar rats with severe colitis, induced by TNBS. The animals were randomized into 3 groups. The control group received 0.5 mL of 0.5% of the vehicle i.p., the DTCM-G group received 22.5 mg/kg body weight DTCM-G in 0.5% i...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2014-01-01
|
Series: | The Scientific World Journal |
Online Access: | http://dx.doi.org/10.1155/2014/813804 |
id |
doaj-435d5da564cb49f8b29118595c6742b8 |
---|---|
record_format |
Article |
spelling |
doaj-435d5da564cb49f8b29118595c6742b82020-11-25T01:22:57ZengHindawi LimitedThe Scientific World Journal2356-61401537-744X2014-01-01201410.1155/2014/813804813804Amelioration of Severe TNBS Induced Colitis by Novel AP-1 and NF-κB Inhibitors in RatsMagdy El-Salhy0Kazuo Umezawa1Odd Helge Gilja2Jan G. Hatlebakk3Doris Gundersen4Trygve Hausken5Section for Gastroenterology, Department of Medicine, Stord Helse-Fonna Hospital, P.O Box 4000, 54 09 Stord, NorwayDepartment of Molecular Target Medicine Screening, School of Medicine, Aichi Medical University, 1-1 Yazakokarimata, Aichi Nagakute, Aichi, JapanDivision of Gastroenterology, Department of Clinical Medicine, University of Bergen, P.O Box 7800, 5020 Bergen, NorwayDivision of Gastroenterology, Department of Clinical Medicine, University of Bergen, P.O Box 7800, 5020 Bergen, NorwayDepartment of Research, Helse-Fonna, Karmsundsgt. 120, 5528 Haugesund, NorwayDivision of Gastroenterology, Department of Clinical Medicine, University of Bergen, P.O Box 7800, 5020 Bergen, NorwayAP-1 and NF-κB inhibitors, namely, DTCM-G and DHMEQ, were investigated in male Wistar rats with severe colitis, induced by TNBS. The animals were randomized into 3 groups. The control group received 0.5 mL of 0.5% of the vehicle i.p., the DTCM-G group received 22.5 mg/kg body weight DTCM-G in 0.5% i.p., and the DHMEQ group received 15 mg/kg body weight DHMEQ i.p., all twice daily for 5 days. The body weight losses and mortality rates were significantly higher in the control group than those in DTCM-G-treated and DHMEQ-treated groups. The endoscopic inflammation scores in the control, DTCM-G-treated, and DHMEQ-treated groups were 6.3 ± 0.7, 1.0 ± 0.3, and 0.7 ± 0.3, respectively (P = 0.004 and 0.02, resp.). The inflammation scores as assessed by the macroscopic appearance were 4.3 ± 0.8, 0.7 ± 0.3, and 1.2 ± 0.4 in the control, DTCM-G-treated, and DHMEQ-treated groups, respectively (P = 0.01 and 0.009, resp.). The histopathological inflammation scores were 6.4 ± 0.7, 2.0 ± 1.0, and 2.2 ± 0.6 in the control, DTCM-G-treated, and DHMEQ-treated groups, respectively (P = 0.03 and 0.01, resp.). It was concluded that DTCM-G and DHMEQ exhibit strong anti-inflammatory and anticancer activities with no apparent toxicity, which make them excellent drug candidates for clinical use in inflammatory bowel diseases.http://dx.doi.org/10.1155/2014/813804 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Magdy El-Salhy Kazuo Umezawa Odd Helge Gilja Jan G. Hatlebakk Doris Gundersen Trygve Hausken |
spellingShingle |
Magdy El-Salhy Kazuo Umezawa Odd Helge Gilja Jan G. Hatlebakk Doris Gundersen Trygve Hausken Amelioration of Severe TNBS Induced Colitis by Novel AP-1 and NF-κB Inhibitors in Rats The Scientific World Journal |
author_facet |
Magdy El-Salhy Kazuo Umezawa Odd Helge Gilja Jan G. Hatlebakk Doris Gundersen Trygve Hausken |
author_sort |
Magdy El-Salhy |
title |
Amelioration of Severe TNBS Induced Colitis by Novel AP-1 and NF-κB Inhibitors in Rats |
title_short |
Amelioration of Severe TNBS Induced Colitis by Novel AP-1 and NF-κB Inhibitors in Rats |
title_full |
Amelioration of Severe TNBS Induced Colitis by Novel AP-1 and NF-κB Inhibitors in Rats |
title_fullStr |
Amelioration of Severe TNBS Induced Colitis by Novel AP-1 and NF-κB Inhibitors in Rats |
title_full_unstemmed |
Amelioration of Severe TNBS Induced Colitis by Novel AP-1 and NF-κB Inhibitors in Rats |
title_sort |
amelioration of severe tnbs induced colitis by novel ap-1 and nf-κb inhibitors in rats |
publisher |
Hindawi Limited |
series |
The Scientific World Journal |
issn |
2356-6140 1537-744X |
publishDate |
2014-01-01 |
description |
AP-1 and NF-κB inhibitors, namely, DTCM-G and DHMEQ, were investigated in male Wistar rats with severe colitis, induced by TNBS. The animals were randomized into 3 groups. The control group received 0.5 mL of 0.5% of the vehicle i.p., the DTCM-G group received 22.5 mg/kg body weight DTCM-G in 0.5% i.p., and the DHMEQ group received 15 mg/kg body weight DHMEQ i.p., all twice daily for 5 days. The body weight losses and mortality rates were significantly higher in the control group than those in DTCM-G-treated and DHMEQ-treated groups. The endoscopic inflammation scores in the control, DTCM-G-treated, and DHMEQ-treated groups were 6.3 ± 0.7, 1.0 ± 0.3, and 0.7 ± 0.3, respectively (P = 0.004 and 0.02, resp.). The inflammation scores as assessed by the macroscopic appearance were 4.3 ± 0.8, 0.7 ± 0.3, and 1.2 ± 0.4 in the control, DTCM-G-treated, and DHMEQ-treated groups, respectively (P = 0.01 and 0.009, resp.). The histopathological inflammation scores were 6.4 ± 0.7, 2.0 ± 1.0, and 2.2 ± 0.6 in the control, DTCM-G-treated, and DHMEQ-treated groups, respectively (P = 0.03 and 0.01, resp.). It was concluded that DTCM-G and DHMEQ exhibit strong anti-inflammatory and anticancer activities with no apparent toxicity, which make them excellent drug candidates for clinical use in inflammatory bowel diseases. |
url |
http://dx.doi.org/10.1155/2014/813804 |
work_keys_str_mv |
AT magdyelsalhy ameliorationofseveretnbsinducedcolitisbynovelap1andnfkbinhibitorsinrats AT kazuoumezawa ameliorationofseveretnbsinducedcolitisbynovelap1andnfkbinhibitorsinrats AT oddhelgegilja ameliorationofseveretnbsinducedcolitisbynovelap1andnfkbinhibitorsinrats AT janghatlebakk ameliorationofseveretnbsinducedcolitisbynovelap1andnfkbinhibitorsinrats AT dorisgundersen ameliorationofseveretnbsinducedcolitisbynovelap1andnfkbinhibitorsinrats AT trygvehausken ameliorationofseveretnbsinducedcolitisbynovelap1andnfkbinhibitorsinrats |
_version_ |
1725124376247926784 |